tirzepatide for obesity fda approval approves weight-loss drug Zepbound to treat sleep apnea Eli Lilly's tirzepatide gained FDA

Administered via a once-weekly injection, semaglutide offers convenience and flexibility for patients, allowing them to integrate the treatment into their lifestyle while working towards their health goals

Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site

According to the Lilly statement, this discovery is concerning because nothing is known about the short- or long-term effects of this molecule in humans, or whether there are any potential impacts on the drugs efficacy, toxicity, or immune reactions

At the highest dose (15 mg), people taking Zepbound lost on average 48 lb., while at the lowest dose (5 mg), people lost on average 34 lb

For some, it shows up as simple fatigue, while others describe it as the blahs or a loss of interest in things they usually enjoy

So maybe theyve- if theyre taking so long to start running a trial, maybe thats because there werent these other uses at all